An evaluation of the pharmacokinetic profile of VSLI (vincristine sulfate liposome injection, 0.16 mg/mL) in patients with malignant melanoma and hepatic dysfunction secondary to metastases

Trial Profile

An evaluation of the pharmacokinetic profile of VSLI (vincristine sulfate liposome injection, 0.16 mg/mL) in patients with malignant melanoma and hepatic dysfunction secondary to metastases

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2013

At a glance

  • Drugs Vincristine (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Jan 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 06 Dec 2007 Status changed from in progress to completed.
    • 30 Oct 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top